Anti-CD19 CAR T-cell therapy remission despite prior anti-CD19 antibody Tafasitamab in relapsed/refractory DLBCL - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34354920/
Tafasitamab (MOR208) is an Fc-enhanced, humanized, monoclonal antibody that targets CD19. The L-MIND (NCT02399085) trial, an open-label, single-arm, phase II study of Tafasitamab (TAFA) plus lenalidomide (LEN), reported progression-free survival...
-
Naveed Saleh, MD, MS – Skipta Team4yrKey Points • Conclusion/Relevance: “The above studies, as well as the report of our patient, delineate that even in patients with unmeasured CD19 expression, subsequent therapies targeting CD19 remain effective. Disease progression Show More
A concise prognostic score system for diffuse large B-cell lymphoma: a retrospective study with long-term follow-up - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34350771/
Aim: To identify risk factors and establish a concise prognostic scoring system in patients with diffuse large B-cell lymphoma (DLBCL). Methods: A total of 131 DLBCL patients were enrolled with...
Predictive Factors of Event-Free Survival at 24 Months in Patients with Peripheral T-cell Lymphoma: A Retrospective Study - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34352996/
doi: 10.4143/crt.2021.270. Online ahead of print. 1 Division of Hematology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea. 2 Department of Internal Medicine, Yongin Severance...
The Role of Interim PET/CT on Survival in Diffuse Large B Cell Lymphoma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34353778/
Background: Diffuse large B cell lymphoma is the most frequent aggressive non-Hodgkin lymphoma. Predicting response and estimating prognosis earlier makes management of this heterogeneous lymphoma more satisfying. Interim PET response...
Anti-CD22 CAR-T Cell Therapy as a Salvage Treatment in B Cell Malignancies Refractory or Relapsed After Anti-CD19 CAR-T therapy - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34239307/
1 Department of Hematology, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, People's Republic of China. 2 The First Central Clinical College of Tianjin Medical University, Tianjin, People's...